한글목차

세계의 경구 단백질 및 펩티드 시장 규모는 2024년에 23억 4,600만 달러로 추정되며, 2025-2031년의 예측 기간 중 CAGR 15.3%로 성장하며, 2031년까지 63억 5,500만 달러로 확대할 것으로 예측되고 있습니다.

이 보고서는 경구용 단백질-펩티드 분야의 최근 관세 조정과 국제적인 전략적 대응 조치에 대해 국경 간 산업 기반, 자본 배분 패턴, 지역 경제의 상호의존성, 공급망 재구축 등의 관점에서 종합적인 평가를 제공합니다.

폴리펩티드 및 단백질 의약품이란 예방, 치료, 진단에 사용되는 폴리펩티드 및 단백질 물질의 생물학적 의약품을 말합니다. 폴리펩티드는 α-아미노산들이 펩티드 사슬로 연결되어 형성된 화합물이며, 단백질 분해의 중간 생성물이기도 합니다. 단백질은 여러 개의 폴리펩티드 사슬이 특정 공간 구조로 얽혀서 형성됩니다. 고분자 단백질의 가수분해에 의해 폴리펩티드가 생성됩니다. 이러한 약품은 생화학 제제이기 때문에 보관 및 운송 환경에 대해 비교적 엄격한 요구 사항이 부과됩니다.

전달 기술의 발전에 따라 주사를 대체할 수 있는 경구제가 새로운 동향으로 떠오르며 환자의 복약 순응도 강화과 시장 성장을 가속하고 있습니다.

당뇨병, 염증성장질환 등 만성질환 치료에 있으며, 경구용 단백질-펩티드 의약품에 대한 수요는 지속적으로 증가하고 있습니다.

나노 전달 시스템 및 효소 억제 인캡슐레이션 기술이 계속 성숙하여 소화관내 분해 문제를 해결하고 제품 개발의 폭을 넓히고 있습니다.

세계 많은 바이오 제약사들이 임상시험과 공동 개발을 추진하며 상업화 과정을 가속화하고 있습니다.

규제와 비용 압박에도 불구하고 경구용 단백질-펩티드 시장은 여전히 높은 잠재력을 지닌 블루오션 분야로 평가받고 있습니다.

이 보고서는 경구용 단백질 및 펩티드 세계 시장에 대해 총판매량, 매출, 매출, 가격, 주요 기업의 시장 점유율 및 순위에 초점을 맞추고 지역/국가, 유형 및 용도별 분석을 종합적으로 제시하는 것을 목표로 합니다.

이 보고서는 경구용 단백질 및 펩티드 시장 규모, 추정치 및 예측치를 판매량(킬로그램) 및 매출액(백만 달러)으로 제시하고, 2024년을 기준 연도, 2020-2031년의 과거 데이터와 예측 데이터를 포함하는 예측 시장 규모를 제시했습니다. 정량적, 정성적 분석을 통해 독자들이 구강용 단백질-펩티드 관련 사업 전략 및 성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 자사 포지셔닝 분석, 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 지원합니다.

시장 세분화

기업별

• Ironwood & Allergan(AbbVie)
• Novo Nordisk
• Synergy Pharmaceuticals(Salix)
• Novartis
• Chiasma(Amryt Pharma)

유형별 부문

• Linaclotide
• Insulin
• Plecanatide
• Cyclosporine
• Octreotide

용도별 부문

• 위·소화기 질환
• 뼈질환
• 당뇨병
• 호르몬 장애

지역별

• 북미
  • 미국
  • 캐나다
• 아시아태평양
  • 중국
  • 일본
  • 한국
  • 동남아시아
  • 인도
  • 호주
  • 기타 아시아태평양
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 네덜란드
  • 북유럽 국가
  • 기타 유럽
• 라틴아메리카
  • 멕시코
  • 브라질
  • 기타 라틴아메리카
• 중동 및 아프리카
  • 튀르키예
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동 및 아프리카

영문목차

The global market for Oral Proteins and Peptides was estimated to be worth US$ 2346 million in 2024 and is forecast to a readjusted size of US$ 6355 million by 2031 with a CAGR of 15.3% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Oral Proteins and Peptides cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Polypeptide and protein drugs refer to the biological drugs of polypeptide and protein substances used for prevention, treatment and diagnosis. Polypeptide is a compound formed by linking a-amino acids together with a peptide chain, and it is also an intermediate product of proteolysis. N polypeptide chains are entangled in a certain spatial structure to form a protein. The hydrolysis of macromolecular proteins produces polypeptides. Such drugs are biochemical preparations and have relatively strict requirements on storage and transportation environment.

With the breakthrough of delivery technology, oral alternatives to injections have become a new trend, improving patient compliance and driving market growth.

The demand for oral protein and peptide drugs for the treatment of chronic diseases (such as diabetes and inflammatory bowel disease) continues to rise.

Nano-delivery systems and enzyme inhibition encapsulation technologies continue to mature, solving gastrointestinal degradation problems and expanding product development space.

Many biopharmaceutical companies around the world are advancing clinical trials and cooperative development to accelerate the commercialization process.

Despite regulatory challenges and cost pressures, the oral protein/peptide market is still seen as a high-potential blue ocean track.

This report aims to provide a comprehensive presentation of the global market for Oral Proteins and Peptides, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Oral Proteins and Peptides by region & country, by Type, and by Application.

The Oral Proteins and Peptides market size, estimations, and forecasts are provided in terms of sales volume (Kg) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Proteins and Peptides.

Market Segmentation

By Company

• Ironwood & Allergan (AbbVie)
• Novo Nordisk
• Synergy Pharmaceuticals (Salix)
• Novartis
• Chiasma (Amryt Pharma)

Segment by Type

• Linaclotide
• Insulin
• Plecanatide
• Cyclosporine
• Octreotide

Segment by Application

• Gastric & Digestive Disorders
• Bone Diseases
• Diabetes
• Hormonal Disorders

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Oral Proteins and Peptides manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Oral Proteins and Peptides in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Oral Proteins and Peptides in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Oral Proteins and Peptides Product Introduction
• 1.2 Global Oral Proteins and Peptides Market Size Forecast
  • 1.2.1 Global Oral Proteins and Peptides Sales Value (2020-2031)
  • 1.2.2 Global Oral Proteins and Peptides Sales Volume (2020-2031)
  • 1.2.3 Global Oral Proteins and Peptides Sales Price (2020-2031)
• 1.3 Oral Proteins and Peptides Market Trends & Drivers
  • 1.3.1 Oral Proteins and Peptides Industry Trends
  • 1.3.2 Oral Proteins and Peptides Market Drivers & Opportunity
  • 1.3.3 Oral Proteins and Peptides Market Challenges
  • 1.3.4 Oral Proteins and Peptides Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Oral Proteins and Peptides Players Revenue Ranking (2024)
• 2.2 Global Oral Proteins and Peptides Revenue by Company (2020-2025)
• 2.3 Global Oral Proteins and Peptides Players Sales Volume Ranking (2024)
• 2.4 Global Oral Proteins and Peptides Sales Volume by Company Players (2020-2025)
• 2.5 Global Oral Proteins and Peptides Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Oral Proteins and Peptides Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Oral Proteins and Peptides Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Oral Proteins and Peptides
• 2.9 Oral Proteins and Peptides Market Competitive Analysis
  • 2.9.1 Oral Proteins and Peptides Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Oral Proteins and Peptides Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Proteins and Peptides as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Linaclotide
  • 3.1.2 Insulin
  • 3.1.3 Plecanatide
  • 3.1.4 Cyclosporine
  • 3.1.5 Octreotide
• 3.2 Global Oral Proteins and Peptides Sales Value by Type
  • 3.2.1 Global Oral Proteins and Peptides Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Oral Proteins and Peptides Sales Value, by Type (2020-2031)
  • 3.2.3 Global Oral Proteins and Peptides Sales Value, by Type (%) (2020-2031)
• 3.3 Global Oral Proteins and Peptides Sales Volume by Type
  • 3.3.1 Global Oral Proteins and Peptides Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Oral Proteins and Peptides Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Oral Proteins and Peptides Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Oral Proteins and Peptides Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Gastric & Digestive Disorders
  • 4.1.2 Bone Diseases
  • 4.1.3 Diabetes
  • 4.1.4 Hormonal Disorders
• 4.2 Global Oral Proteins and Peptides Sales Value by Application
  • 4.2.1 Global Oral Proteins and Peptides Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Oral Proteins and Peptides Sales Value, by Application (2020-2031)
  • 4.2.3 Global Oral Proteins and Peptides Sales Value, by Application (%) (2020-2031)
• 4.3 Global Oral Proteins and Peptides Sales Volume by Application
  • 4.3.1 Global Oral Proteins and Peptides Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Oral Proteins and Peptides Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Oral Proteins and Peptides Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Oral Proteins and Peptides Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Oral Proteins and Peptides Sales Value by Region
  • 5.1.1 Global Oral Proteins and Peptides Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Oral Proteins and Peptides Sales Value by Region (2020-2025)
  • 5.1.3 Global Oral Proteins and Peptides Sales Value by Region (2026-2031)
  • 5.1.4 Global Oral Proteins and Peptides Sales Value by Region (%), (2020-2031)
• 5.2 Global Oral Proteins and Peptides Sales Volume by Region
  • 5.2.1 Global Oral Proteins and Peptides Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Oral Proteins and Peptides Sales Volume by Region (2020-2025)
  • 5.2.3 Global Oral Proteins and Peptides Sales Volume by Region (2026-2031)
  • 5.2.4 Global Oral Proteins and Peptides Sales Volume by Region (%), (2020-2031)
• 5.3 Global Oral Proteins and Peptides Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Oral Proteins and Peptides Sales Value, 2020-2031
  • 5.4.2 North America Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Oral Proteins and Peptides Sales Value, 2020-2031
  • 5.5.2 Europe Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Oral Proteins and Peptides Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Oral Proteins and Peptides Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Oral Proteins and Peptides Sales Value, 2020-2031
  • 5.7.2 South America Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Oral Proteins and Peptides Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Oral Proteins and Peptides Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Oral Proteins and Peptides Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Oral Proteins and Peptides Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Oral Proteins and Peptides Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Oral Proteins and Peptides Sales Value, 2020-2031
  • 6.3.2 United States Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Oral Proteins and Peptides Sales Value, 2020-2031
  • 6.4.2 Europe Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Oral Proteins and Peptides Sales Value, 2020-2031
  • 6.5.2 China Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Oral Proteins and Peptides Sales Value, 2020-2031
  • 6.6.2 Japan Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Oral Proteins and Peptides Sales Value, 2020-2031
  • 6.7.2 South Korea Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Oral Proteins and Peptides Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Oral Proteins and Peptides Sales Value, 2020-2031
  • 6.9.2 India Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Ironwood & Allergan (AbbVie)
  • 7.1.1 Ironwood & Allergan (AbbVie) Company Information
  • 7.1.2 Ironwood & Allergan (AbbVie) Introduction and Business Overview
  • 7.1.3 Ironwood & Allergan (AbbVie) Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Ironwood & Allergan (AbbVie) Oral Proteins and Peptides Product Offerings
  • 7.1.5 Ironwood & Allergan (AbbVie) Recent Development
• 7.2 Novo Nordisk
  • 7.2.1 Novo Nordisk Company Information
  • 7.2.2 Novo Nordisk Introduction and Business Overview
  • 7.2.3 Novo Nordisk Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Novo Nordisk Oral Proteins and Peptides Product Offerings
  • 7.2.5 Novo Nordisk Recent Development
• 7.3 Synergy Pharmaceuticals (Salix)
  • 7.3.1 Synergy Pharmaceuticals (Salix) Company Information
  • 7.3.2 Synergy Pharmaceuticals (Salix) Introduction and Business Overview
  • 7.3.3 Synergy Pharmaceuticals (Salix) Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Synergy Pharmaceuticals (Salix) Oral Proteins and Peptides Product Offerings
  • 7.3.5 Synergy Pharmaceuticals (Salix) Recent Development
• 7.4 Novartis
  • 7.4.1 Novartis Company Information
  • 7.4.2 Novartis Introduction and Business Overview
  • 7.4.3 Novartis Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Novartis Oral Proteins and Peptides Product Offerings
  • 7.4.5 Novartis Recent Development
• 7.5 Chiasma (Amryt Pharma)
  • 7.5.1 Chiasma (Amryt Pharma) Company Information
  • 7.5.2 Chiasma (Amryt Pharma) Introduction and Business Overview
  • 7.5.3 Chiasma (Amryt Pharma) Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Chiasma (Amryt Pharma) Oral Proteins and Peptides Product Offerings
  • 7.5.5 Chiasma (Amryt Pharma) Recent Development

8 Industry Chain Analysis

• 8.1 Oral Proteins and Peptides Industrial Chain
• 8.2 Oral Proteins and Peptides Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Oral Proteins and Peptides Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Oral Proteins and Peptides Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer